Therefore, 54 potential leads were selected based on their inhibitory effect on MLL-rearranged ALL cells, and further validated at 100 nM and 10 nM concentrations, yielding a narrow selection of very potent compounds (Supplementary Figure S1D–F). Here, KMT2A is linked to acute lymphoblastic leukemia.